Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Publikationen
Ergebnisse pro Seite:  10

Gärtner, J; Gahr, S; Reinholz, U et al.

Sinnvolle Strategien für die Versorgung im Delir

Deutsches Ärzteblatt. Bd. 3. 2022 S. 14-17


Tilch, Marie-Kristin; Schranz, Melanie; Moringlane, Alice et al.

Struggling with extensive informed consent procedures for cancer trials-is there even a benefit for the patients?

SUPPORTIVE CARE IN CANCER. Bd. 30. H. 8. 2022 S. 6593-6602



Bell, Elisabeth; Desuki, Alexander; Karbach, Susanne et al.

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report

EUROPEAN HEART JOURNAL-CASE REPORTS. Bd. 6. H. 10. 2022


Stickdorn, Judith; Stein, Lara; Arnold-Schild, Danielle et al.

Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors

ACS NANO. Bd. 16. H. 3. 2022 S. 4426-4443


Agaimy, Abbas; Arbogast, Helmut; Barth, Thomas et al.

Thanks to the Reviewers of The Pathologist

PATHOLOGE. Bd. 43. H. 1. 2022 S. 3-4


Eichler, Martin; Singer, Susanne; Hentschel, Leopold et al.

The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients-results of a Nationwide Observational Study (PROSa)

BRITISH JOURNAL OF CANCER. Bd. 126. H. 9. 2022 S. 1346-1354


Mack, Matthias; Broche, Julian; George, Stephen et al.

The DKTK EXLIQUID consortium - exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

JOURNAL OF LABORATORY MEDICINE. Bd. 46. H. 4. 2022 S. 321-330


Mack, Matthias; Broche, Julian; George, Stephen et al.

The DKTK EXLIQUID consortium exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

JOURNAL OF LABORATORY MEDICINE. Bd. 46. H. 4. 2022 S. 321-330